2018 Competitor Analysis: PRAME-Targeted Immunotherapy – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Competitor
Analysis: PRAME-Targeted Immunotherapy”
report has been added
to ResearchAndMarkets.com’s offering.

This Competitive Intelligence report analyzes the competitive field of
PRAME-Targeted Immunotherapies as of June 2018 in a tabulated format
with structured listings of industry-relevant data.

The report includes a compilation of currently active projects in
research and development of passive and active immunotherapy and
adoptive cell therapy targeting PRAME. In addition, the report lists
company- and institution-specific R&D pipelines of PRAME-Targeted
Immunotherapies.

PRAME (preferentially expressed antigen in melanoma), a member of the
cancer-testis antigen family, has been shown to have increased
expression in solid tumors. PRAME was first identified as a
tumor-associated antigen through analysis of the specificity of
tumor-reactive T-cell clones derived from a patient with metastatic
cutaneous melanoma.

Subsequently, it has been shown that PRAME is expressed in many
malignant neoplasms, including cutaneous melanoma, breast carcinoma,
non-small cell lung cancer, and leukemia, whereas normal healthy tissues
express minimal or no PRAME, with the exception of the testis and
endometrium.

It was shown that PRAME-specific CD8+ T cells isolated from healthy
individuals and patients with advanced melanoma were able to recognize
and lyse cells expressing HLA class I and high levels of PRAME. Thus,
PRAME is a potential candidate for cancer immunotherapy because it is
expressed by a variety of tumours and can induce T-cell immune responses.

Competitor projects are listed in a tabular format providing
information on:

  • Drug Codes
  • Target/Mechanism of Action
  • Class of Compound
  • Company
  • Product Category
  • Indication
  • R&D Stage
  • Additional comments with a hyperlink leading to the source of
    information

Key Topics Covered

1. PRAME-Targeted Immunotherapy

  • PRAME-Targeted Selective and Multi-Antigen Cancer Vaccines
  • PRAME-Selective Cellular & Recombinant Immunotherapies
  • PRAME-Specific, Multi-Target Adoptive Cell Therapy

2. Corporate & Institutional PRAME Immunotherapy R&D Pipelines

For more information about this report visit https://www.researchandmarkets.com/research/n5txrb/2018_competitor?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Oncology
Drugs